Xavant and Promedia Medizintechnik at Münsteraner Anästhesie-Symposium in Münster, Germany (28 – 30 Nov 2019)

Münster, Germany, 28 – 30 November 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 51st Münsteraner Anästhesie-Symposium in Münster, Germany from 28 – 30 November 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about the Stimpod…

Xavant and Promedia Medizintechnik at the 21st Capital Congress of the DGAI in Berlin (19 – 21 September 2019)

Berlin, Germany, 19 – 21 September 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 21st Capital Congress of the Deutsche Gesellschaft für Anästhesiologie & Intensivmedizin in Berlin, Germany from 19 to 21 September 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new…

Xavant Reveals One-Touch NMT Monitor at ASA Annual Meeting (USA)

San Francisco, USA, 13 October 2018 -Xavant Technology (Pty) Ltd is attending the American Society of Anesthesiologists (ASA) Conference 2018 in San Franciso from 13 to 17 October. The company, who is a leading developer of quantitative neuromuscular transmission monitors (NMT monitors) revealed their latest product for the anesthesiology community, the Stimpod NMS450X. The new…

Xavant Technology exhibiting at the Physio First Conference (UK)

NOTTINGHAM, United Kingdom, 9 March 2018 – Xavant Technology (Pty) Ltd is attending the Physio First Conference in Nottingham, the United Kingdom, from 27 to 29 April 2018. The company, who is a leading developer of nerve stimulators for regional and general anesthesia, obtained clearance from the U.S Food and Drug Administration’s (FDA) in June 2017 to distribute…

Stimpod NMS460 Receives FDA Clearance (USA)

Pretoria, South Africa – Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive…